SUMMARY - Members
Emycare
Emycare développe une solution de phénotypage comportemental pour la prise en charge clinique personnalisée de l’obésité. Notre approche permet d’établir un diagnostic précis du patient, orientant son parcours de soins et assurant un suivi numérique personnalisé, afin de maintenir durablement son engagement et la modification de ses comportements. Emycare est développé en association avec un laboratoire de recherche spécialisé en sciences motivationnelles et comportementales.
Rejoindre PreciDIAB est une évidence pour Emycare. Nous partageons un même objectif : mieux comprendre les patients pour personnaliser la prévention et la prise en charge de l'obésité. Basés dans les Hauts-de-France, où ces enjeux sont majeurs, nous sommes convaincus que c’est par la collaboration entre chercheurs, cliniciens et industriels que naîtront des solutions réellement innovantes pour les patients.
EW2 Health
EW2Health is building the world’s first predictive behavioral monitoring platform for obesity care.
Using our patented numberless scales and Predictive Behavioral Analytics technology, we turn weight data into actionable insights for patients, clinics, pharmacies, and fitness providers, unlocking a truly integrated, personalized, and effective weight-loss ecosystem.
We’re very excited to join the PreciDIAB Club. As a clinician-scientist, I know collaboration is essential to improve outcomes in obesity and metabolic care. At EW2Health, we’re eager to share our results and the real-world data we’re gathering from the many clinics and apps now using our platform, not just for our algorithm, but for our strong integration with partners across the obesity care ecosystem. I’m really looking forward to working with your professors and staff to explore these insights together and advance effective, patient-friendly digital therapies.
GDBiotech
GDBiotech is a spin-off of the Genes Diffusion group which hosts a portfolio of technologies and patents finding applications in fields as varied as molecular diagnostic (qPCR) and immunological (multiplex ELISA) solutions, bioinformatics tools for the automation of DNA sequence analyzes, and the study of the microbiota.
Our company has no direct link with human health research. However, we have developed or applied for our activity many technological and even scientific methods similar to those applicable in human health research. We would like to share with the members of this network around these favorite subjects.
Novo Nordisk
Novo Nordisk is an international pharmaceutical company headquartered in Copenhagen, Denmark. We specialize in the treatment of diabetes and other serious chronic diseases such as obesity, rare bleeding diseases and growth disorders.
We employ more than 45,000 people in 80 subsidiaries around the world. Our healthcare solutions are available in 169 countries.
Joining the PreciDIAB initiative club means participating in excellent research on diabetes, but also collaborating with public and private institutional partners in prevention and health promotion programs.
StarkAge Therapeutics
StarkAge Therapeutics is a privately-held, early-stage biotechnology company and pioneer in the field of senescence. Based in France in Lille, it was founded in 2018 by Dr. Thierry Mathieu on the idea that the elimination by targeted immunotherapy of senescent cells specific to certain age-related diseases could bring significant therapeutic benefits to patients. Initially, we focus on pulmonary fibrosis and hepatic fibrosis (NASH/NAFLD)
Joining the PreciDIAB club was obvious for a young start-up like ours. Being able to discuss with academic and industrial experts, and share our experiences and knowledge, is a major source of mutual enrichment.
